Found: 7
Select item for more details and to access through your institution.
Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 11, p. 2609, doi. 10.1007/s00262-022-03180-x
- By:
- Publication type:
- Article
Génomique, thérapie ciblée et CAPI: vers une prise en charge basée sur l’analyse moléculaire des CAPI ?
- Published in:
- Oncologie (Tech Science Press), 2008, v. 10, n. 12, p. 718, doi. 10.1007/s10269-008-0985-1
- By:
- Publication type:
- Article
Cancer de la prostate métastatique: quoi de neuf depuis le docétaxel ?
- Published in:
- Oncologie (Tech Science Press), 2008, v. 10, n. 11, p. 648, doi. 10.1007/s10269-008-0965-5
- By:
- Publication type:
- Article
Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2014, v. 17, n. 3, p. 220, doi. 10.1038/pcan.2014.17
- By:
- Publication type:
- Article
Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients.
- Published in:
- 2007
- By:
- Publication type:
- Journal Article
Combination of Gemcitabine and Doxorubicin in Rapidly Progressive Metastatic Renal Cell Carcinoma and/or Sarcomatoid Renal Cell Carcinoma.
- Published in:
- Oncology, 2011, v. 80, n. 3/4, p. 214, doi. 10.1159/000329078
- By:
- Publication type:
- Article